Patient guide - fruquintinib

What to expect when starting FRUZAQLA®▼ (fruquintinib): A guide for your patients

This digital guide has been created for patients with mCRC who have been prescribed FRUZAQLA. It outlines important information, including what patients should discuss with their doctors before starting treatment, how to take FRUZAQLA, and potential adverse events they may experience.

Download the guide here

This patient guide should only be downloaded and shared offline or ordered via one of our representatives, contactable here. This website is not intended to be shared with patients or considered appropriate for them to access.

Illustration of a doctor talking with a professional woman

Accessing and discussing materials with your Takeda representative

We've developed resources aimed at providing guidance and support for the management of patients undergoing treatment with FRUZAQLA. If you would like a hard copy or would like to discuss a topic further, simply use the button below to contact your Takeda representative.

Get in touch

FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, with or without an anti-VEGF therapy, and, if RAS wildtype and medically appropriate, an anti-EGFR therapy.¹

EGFR = epidermal growth factor receptor; mCRC = metastatic colorectal cancer; VEGF = vascular endothelial growth factor.

1. FRUZAQLA Summary of Product Characteristics.

To enjoy the full experience of OncoConnect, including the ability to like and bookmark content for easy access via your account section, please register or login now.

Related content

Image of a beach on an island with ‘SOS’ written in rocks

PI Fruzaqla▼ (fruquintinib)

FRUZAQLA®▼ (fruquintinib): Clinically proven – with generally consistent results across two pivotal phase 3 trials¹⁻³

FRUZAQLA is an oral, targeted treatment for people living with previously treated mCRC.³ It is a highly selective small molecule tyrosine kinase inhibitor that works by inhibiting VEGF receptors 1, 2, and 3.³

FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan- based chemotherapy, with or without anti-VEGF therapy, and if RAS wild type and medically appropriate, an anti-EGFR therapy.³

guide

PI Fruzaqla▼ (fruquintinib)

A practical guide for FRUZAQLA®▼ (fruquintinib)

Approx. 10 mins

This digital resource provides a summary of information that you might need before starting your patients on FRUZAQLA, including dosing, key considerations, special warnings, and how to manage adverse events.